RoosterBio Launches the Regenerative Medicine Industry’s First Xeno-Free hMSC Cell Banks to Advance and Simplify Stem Cell Biomanufacturing
FREDERICK, MARYLAND, May 04, 2017–At a CAGR of 23.2% and estimated revenue of $68B by 2020, the Regenerative Medicine (“RM”) industry continues to call for new tools designed to accelerate this aggressive growth. Based on strong RM market demand, RoosterBio Inc today announces the launch of xeno-free (“XF”) human bone-marrow derived mesenchymal stem/stromal cell (hMSC) products.
RoosterBio is an innovative mesenchymal stem cell (MSC) company that is focusing on democratizing stem cell manufacturing and ushering in a new era of regenerative medicine. 2016 has been a massive year for the company, as it recently announced a 
